Beth yw'r triniaethau newydd sydd ar gael dan y gronfa triniaethau newydd fesul blwyddyn yn nhymor y Senedd hon?
In the period April 2021 to March 2025, 343 treatments have been made available through the New Treatment Fund.
Since April 2023, all details of medicines supported by the New Treatment Fund have been published by the All Wales Therapeutics and Toxicology Centre (AWTTC) and can be accessed at: The New Treatment Fund - All Wales Therapeutics and Toxicology Centre.
Treatments approved in 2021 and 2022 and the details of some medicines which have been approved since April 2025, are not included in the data published via the link above.
The medicines added to the New Treatment Fund between 2021 and 2023 (prior to the ATTWC publication link) are as follows:
Period: 2021-22
|
Treatment |
Indication |
|
Abemaciclib |
Breast cancer |
|
Adalimumab |
Rheumatoid arthritis |
|
Adalimumab |
Ulcerative colitis |
|
Amikacin liposomal |
Nontuberculous mycobacterial (NTM) lung infections |
|
Apalutamide |
Metastatic prostate cancer |
|
Apalutamide |
Non-metastatic prostate cancer |
|
Atezolizumab |
Lung cancer |
|
Atezolizumab |
Urothelial cancer |
|
Atidarsagene autotemcel |
Metachromatic leukodystrophy |
|
Avelumab |
Urothelial cancer |
|
Azacitidine |
Leukaemia |
|
Belimumab |
Systemic lupus erythematosus |
|
Bempedoic acid |
Primary hypercholesterolaemia or mixed dyslipidaemia |
|
Bempedoic acid-ezetimibe |
Primary hypercholesterolaemia or mixed dyslipidaemia |
|
Berotralstat |
Hereditary angioedema |
|
Bimekizumab |
Psoriasis |
|
Bortezomib |
Multiple myeloma |
|
Budesonide |
eosinophilic oesophagitis |
|
Cabotegravir |
HIV |
|
Cannabidiol |
Seizures associated with tuberous sclerosis complex |
|
Cenobamate |
Epilepsy |
|
Chlormethine gel |
Lymphoma |
|
Clostridium botulinum neurotoxin type A |
Sialorrhoea due to neurological/neurodevelopmental disorders |
|
Clostridium botulinum type A toxin-haemagglutinin complex |
Focal spasticity |
|
Conestat alfa |
Hereditary angioedema |
|
Cytarabine |
Leukaemia |
|
Dabigatran etexilate |
Venous thromboembolic events |
|
Dapagliflozin |
Chronic kidney disease |
|
Daratumumab |
Multiple myeloma |
|
Dexamethasone |
Multiple myeloma |
|
Diroximel fumarate |
Multiple sclerosis |
|
Dolutegravir |
HIV |
|
Dostarlimab |
Endometrial cancer |
|
Dupilumab |
Severe asthma |
|
Elosulfase alfa |
Mucopolysaccharidosis |
|
Empagliflozin |
Heart failure |
|
Entrectinib |
Lung cancer |
|
Entrectinib |
Solid tumours |
|
Enzalutamide |
Prostate cancer |
|
Etanercept |
Rheumatoid arthritis |
|
Etravirine |
HIV |
|
Everolimus |
Refractory partial-onset seizures |
|
Fedratinib |
Disease-related splenomegaly/myelofibrosis |
|
Filgotinib |
Ulcerative colitis |
|
Fremanezumab |
Migraine |
|
Fulvestrant |
Breast cancer |
|
Givosiran |
Acute hepatic porphyria |
|
Glecaprevir/pibrentasvir |
Hepatitis C |
|
Guselkumab |
Psoriatic arthritis |
|
Inclisiran |
Hypercholesterolaemia |
|
Indacaterol acetate/glycopyrronium bromide/mometasone furoate |
Asthma |
|
Infliximab |
Rheumatoid arthritis |
|
Ipilimumab |
Colorectal cancer |
|
Ipilimumab |
Renal cancer |
|
Ixekizumab |
Axial spondyloarthritis |
|
Mexiletine |
Myotonia |
|
Midostaurin |
Mastocytosis |
|
Mogamulizumab |
Mycosis fungoides and Sézary syndrome |
|
Nintedanib |
Progressive fibrosing interstitial lung diseases |
|
Niraparib |
Ovarian fallopian tube and peritoneal cancer |
|
Nitisinone |
Alkaptonuria |
|
Nivolumab |
Colorectal cancer |
|
Nivolumab |
Lung cancer |
|
Nivolumab |
Oesophageal & gastro-oesophageal junction cancer |
|
Nivolumab |
Oesophageal cancer |
|
Nivolumab |
Renal cancer |
|
Nivolumab |
Squamous cell carcinoma |
|
Odevixibat |
Intrahepatic cholestasis |
|
Onasemnogene abeparvovec |
Spinal muscular atrophy |
|
Osimertinib |
Lung cancer |
|
Palforzia |
Peanut allergy |
|
Pegcetacoplan |
Paroxysmal nocturnal haemoglobinuria |
|
Pembrolizumab |
colorectal cancer |
|
Pembrolizumab |
Hodgkin lymphoma |
|
Pembrolizumab |
Lung cancer |
|
Pembrolizumab |
Melanoma |
|
Pembrolizumab |
Oesophageal & gastro-oesophageal junction cancer |
|
Pemigatinib |
Cholangiocarcinoma |
|
Perampanel |
Seizures |
|
Ponesimod |
Multiple sclerosis |
|
Ravulizumab |
Atypical haemolytic uraemic syndrome |
|
Ravulizumab |
Paroxysmal nocturnal haemoglobinuria |
|
Rilpivirine |
HIV |
|
Risdiplam |
Spinal muscular atrophy |
|
Rivaroxaban |
venous thromboembolism |
|
Romosozumab |
Severe osteoporosis |
|
Sapropterin |
Phenylketonuria |
|
Secukinumab |
Axial spondyloarthritis |
|
Secukinumab |
Psoriasis |
|
Selpercatinib |
Lung cancer |
|
Selpercatinib |
Thyroid cancer |
|
Selumetinib |
Plexiform neurofibromas |
|
Solriamfetol |
Daytime sleepiness caused by narcolepsy |
|
Sotorasib |
Lung cancer |
|
Tepotinib |
Lung cancer |
|
Thalidomide |
Multiple myeloma |
|
Tirbanibulin |
Keratosis |
|
Tofacitinib |
Juvenile idiopathic arthritis |
|
Tucatinib |
Breast cancer |
|
Upadacitinib |
Psoriatic arthritis |
|
Upadacitinib |
Rheumatoid arthritis |
|
Ustekinumab |
Plaque psoriasis |
|
Venetoclax |
Leukaemia |
2022-23
|
Treatment |
Indication |
|
Abemaciclib |
Breast cancer |
|
Abrocitinib |
Dermatitis |
|
Alpelisib |
Breast cancer |
|
Ambrisentan |
Hypertension |
|
Asciminib |
Leukaemia |
|
Asfotase alfa |
Hypophosphatasia |
|
Ataluren |
Duchenne muscular dystrophy |
|
Atezolizumab |
Lung cancer |
|
Avacopan |
Granulomatosis with polyangiitis or microscopic polyangiitis |
|
Avalglucosidase alfa |
Pompe disease |
|
Avatrombopag |
Thrombocytopenia |
|
Axicabtagene ciloleucel |
Lymphoma |
|
Azacitidine |
Acute myeloid leukaemia |
|
Bedaquiline |
Tuberculosis |
|
Bevacizumab |
Carcinoma of the cervix |
|
Brexucabtagene autoleucel |
Leukaemia |
|
Brivaracetam |
Epilepsy |
|
Brolucizumab |
Diabetic macular oedema |
|
Cabozantinib |
Hepatocellular carcinoma |
|
Cannabidiol |
Tuberous sclerosis complex |
|
Cariprazine |
Schizophrenia |
|
Cemiplimab |
Squamous cell carcinoma |
|
Daratumumab |
Multiple myeloma |
|
Dexamethasone |
Diabetic macular oedema |
|
Difelikefalin |
Pruritus |
|
Dupilumab |
Asthma |
|
Durvalumab |
Lung cancer |
|
Eladocagene exuparvovec |
L-amino acid decarboxylase deficiency |
|
Elbasvir-grazoprevir |
Hepatitis C |
|
Eptinezumab |
Migraine |
|
Everolimus |
Renal angiomyolipoma and subependymal giant cell astrocytoma associated with tuberous sclerosis complex |
|
Faricimab |
Diabetic macular oedema |
|
Faricimab |
Wet age-related macular degeneration |
|
Fenfluramine |
Dravet syndrome |
|
Ferric maltol |
Iron deficiency |
|
Finerenone |
Kidney disease |
|
Fostamatinib |
Thrombocytopenia |
|
Guselkumab |
Psoriatic arthritis |
|
Hydrocortisone |
Adrenal hyperplasia |
|
Ibrutinib |
Leukaemia |
|
Icosapent ethyl |
Cardiovascular events |
|
Imlifidase |
Kidney disease |
|
Insulin degludec |
Diabetes mellitus |
|
Ipilimumab |
Pleural mesothelioma |
|
Ixazomib |
Multiple myeloma |
|
Lacosamide |
Epilepsy |
|
Lenvatinib |
Renal cell carcinoma |
|
Lumasiran |
Hyperoxaluria |
|
Maribavir |
Cytomegalovirus |
|
Mercaptamine bitartrate |
Nephropathic cystinosis |
|
Migalastat hydrochloride |
Fabry disease |
|
Mobocertinib |
Lung cancer |
|
Nintedanib |
Pulmonary fibrosis |
|
Nirmatrelvir-ritonavir |
COVID-19 |
|
Nivolumab |
gastric gastro-oesophageal junction or oesophageal adenocarcinoma |
|
Nivolumab |
Lung cancer |
|
Nivolumab |
Oesophageal squamous cell carcinoma |
|
Nivolumab |
Pleural mesothelioma |
|
Nivolumab |
Urothelial cancer |
|
Onasemnogene abeparvovec |
Spinal muscular atrophy |
|
Ozanimod |
Ulcerative colitis |
|
Palbociclib |
Breast cancer |
|
Pembrolizumab |
Breast cancer |
|
Pembrolizumab |
Cervical cancer |
|
Pembrolizumab |
Melanoma |
|
Pembrolizumab |
Renal cancer |
|
Pembrolizumab |
Renal cell carcinoma |
|
Polatuzumab vedotin |
Lymphoma |
|
Regorafenib |
Colorectal cancer |
|
Relugolix – estradiol - norethisterone acetate |
Uterine fibroids |
|
Risankizumab |
Arthritis |
|
Rituximab |
Pemphigus vulgaris |
|
Roxadustat |
Anaemia in kidney disease |
|
Sacituzumab govitecan |
Breast cancer |
|
Setmelanotide |
Obesity |
|
Sofosbuvir - velpatasvir |
Hepatitis |
|
Somatrogon |
Growth disturbance |
|
Sotrovimab |
COVID-19 |
|
Teduglutide |
Short bowel syndrome |
|
Teriflunomide |
Multiple sclerosis |
|
Tezepelumab |
Asthma |
|
Tocilizumab |
COVID-19 |
|
Tralokinumab |
Dermatitis |
|
Trastuzumab deruxtecan |
Breast cancer |
|
Trifluridine-tipiracil |
Gastric cancer or gastro-oesophageal junction adenocarcinoma |
|
Upadacitinib |
Ankylosing spondylitis |
|
Upadacitinib |
Axial spondyloarthritis |
|
Upadacitinib |
Dermatitis |
|
Upadacitinib |
Ulcerative colitis |
|
Venetoclax |
Leukaemia |
|
Voclosporin |
Lupus nephritis |
|
Vutrisiran |
Amyloidosis |
|
Zanubrutinib |
Waldenström's macroglobulinaemia |